C5 (UK) will be holding its 19th Forum on Biotech Patenting on October 6-7, 2010 in London, England. Regulators, biotech practitioners, and experienced in-house counsel will provide information on:
• The latest strategies for adapting one's patent practice to the EPO rule changes;
• The EPO examiner's perspective on patenting biotechnological inventions;
• Satisfying the requirements for industrial applicability following HGS v. Eli Lilly;
• Drafting of Second Medical Use Claims after G2/08: How to ensure that a patent is likely to be valid;
• The current state of play for biosimilars in the U.S. and in Europe: Where do we stand and what does the future hold?
• Patent strategies for therapeutic RNAi;
• The scope of EU legislation on the protection of biotechnological inventions: Monsanto v. Cefetra and the biotech directive; and
• The practical impact of groundbreaking U.S. case law and policy developments.
In particular, C5 faculty will offer presentations on the following topics:
• Keynote address: A judicial view on biotech patenting litigation -- Hon. Lord Justice Jacob, Court of Appeal of England and Wales (UK);
• "Raising the bar": Examining and debating the impact of the EPO's new standards and rule changes on biotech inventions;
• The EPO's perspective on patenting biotechnological inventions -- Dr. Aliki Nichogiannopoulou, Director, Biotechnology, European Patent Office (Germany);
• An overview of the year's most important biotech cases and other landmark decisions;
• HGS v. Eli Lilly: Satisfying the requirements for industrial applicability;
• The scope of second medical use claims after G2/08;
• Supplementary Protection Certificates (SPCs): Where do we stand and what does the future hold?
• Biosimilars and biologics: Comparing and contrasting European and U.S. standards;
• Patent strategies for therapeutic RNAi;
• G1/08 and G2/07: Patentability of plant breeding methods in relation to "essentially biological processes";
• The biotech directive: Highlighting the challenges with Europe's two legal systems;
• Stem cells -- The latest controversies;
• Gene patents to be limited to function? The Monsanto case (C 428/08);
• Major case law and policy developments in the U.S.; and
• Developments in patent litigation procedure and cross-jurisdictional litigation management strategies.
An additional pre-conference workshop, entitled "Drafting Successful Patent Applications for Biotechnology-Related Inventions," will be offered on October 5, 2010. In this workshop, C5 faculty will discuss the process of drafting complex claims and specifications, and provide attendees with the tools needed to draft biotech claims and specifications that will withstand future challenges.
A post-conference workshop, entitled "Managing Due Diligence: Scrutiny of Your Patent Portfolio," will be offered on October 8, 2010. In this workshop, C5 faculty will use case studies to focus on the key areas attendees need to consider in M&A transactions.
The agenda for the Biotech Patenting conference can be found here. A complete brochure for this conference, including an agenda, description of the sessions, list of speakers, and registration form can be downloaded here.
The registration fee for the conference is £1499 ($2,328.00), for the conference and one workshop £1898 ($2,947.66), and for the conference and both workshop £2197 ($3,412.02). Those interested in registering for the conference can do so here, by calling +44 (0) 20 7878 6888, by faxing a registration form to +44 (0) 20 7878 6896, or by e-mailing [email protected].
Comments